– Brings invaluable expertise in leading,
operating and scaling global businesses throughout his career in
aerospace, transportation and integrated solutions –
SAN
FRANCISCO, Jan. 30, 2023 /PRNewswire/
-- Invitae (NYSE: NVTA), a leading medical genetics
company, has announced that aerospace, transportation and
industrial supplies veteran William H.
Osborne has been appointed to its board of directors and
will also serve on its audit committee, effective January 26, 2023.
"We are pleased to welcome William
(Bill) Osborne to our board of directors and look forward to
working with him and taking full advantage of his considerable
track record of both operational and governance leadership. Bill
has guided multiple companies to achieve transformational growth,
scale and innovation, globally," said Ken
Knight, president and chief executive officer of Invitae.
"Bill's experience in the CEO role and his tenure at both Boeing
Company and Navistar demonstrate a breadth and depth of leadership
within global enterprises. While at Boeing, Bill served in several
senior management positions, led its manufacturing council and
provided oversight of corporate environmental health and safety.
These roles will offer insight into how companies like ours, in
highly competitive industries, can innovate to expand and enhance
our service to our patients and customers and streamline processes
while fulfilling broader responsibilities to employees and the
environment. His perspective and experience from outside the
genetics industry will be a valuable addition to our board as we
scale our business and bring genetic information into mainstream
medicine."
Mr. Osborne recently retired as senior vice president of
operations and total quality for Boeing Defense, Space &
Security (BDS), one of The Boeing Company's three business units.
The Boeing Company is the world's largest aerospace company and a
leading manufacturer of commercial jetliners and defense, space and
security systems. He also maintained oversight for environment,
health & safety at BDS, was named to lead Boeing's
manufacturing council and served on the Boeing executive
council.
Before joining Boeing, he was senior vice president of global
manufacturing and quality at Navistar International Corporation, a
holding company whose subsidiaries and affiliates produce
International® brand commercial and military
trucks. Before joining Navistar, he was president and chief
executive officer of Federal Signal Corporation, a designer and
manufacturer of a suite of products and integrated solutions for
municipal, governmental, industrial and airport customers, from
2008 to 2010.
"Invitae's focus on making medical genetics affordable,
accessible and ubiquitous has the potential to fundamentally
transform healthcare. The company is leading the creation of a new
industry, creating a network of patients and their data that may
support faster diagnoses, better treatments and eventually the
eradication of disease," said Osborne. "I'm delighted and grateful
for the opportunity to serve the board and the company at this
exciting time and look forward to helping the team deliver on its
mission to help improve healthcare for billions of people."
Mr. Osborne currently serves on the board of directors at Quaker
Houghton, a global industrial products company where he serves on
the compensation, human resources and sustainability committees; as
well as at Armstrong World Industries, a leader in the design,
innovation and manufacture of ceiling and wall system solutions in
America, where he serves on the compensation and governance
committees.
About Invitae
Invitae (NYSE: NVTA) is a leading
medical genetics company trusted by millions of patients and their
providers to deliver timely genetic information using digital
technology. We aim to provide accurate and actionable answers to
strengthen medical decision-making for individuals and their
families. Invitae's genetics experts apply a rigorous approach to
data and research, serving as the foundation of their mission to
bring comprehensive genetic information into mainstream medicine to
improve healthcare for billions of people.
To learn more, visit invitae.com and follow for
updates on Twitter, Instagram, Facebook and
LinkedIn @Invitae.
Safe Harbor Statement
This press release contains
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995, including statements
relating to the company's belief that Mr. Osborne's perspective and
experience will have a positive impact on the company and its
customers; that the company's mission has the potential to
transform healthcare; and that the company is leading the creation
of a new industry and creating a network of patients and their data
that may support better health outcomes. Forward-looking statements
are subject to risks and uncertainties that could cause actual
results to differ materially, and reported results should not be
considered as an indication of future performance. These risks and
uncertainties include, but are not limited to: the company's
history of losses; the company's ability to compete; the company's
failure to manage growth effectively; the company's need to scale
its infrastructure in advance of demand for its tests and to
increase demand for its tests; the company's ability to use rapidly
changing genetic data to interpret test results accurately and
consistently; security breaches, loss of data and other
disruptions; laws and regulations applicable to the company's
business; and the other risks set forth in the company's filings
with the Securities and Exchange Commission, including the risks
set forth in the company's Quarterly Report on Form 10-Q for the
quarter ended September 30, 2022.
These forward-looking statements speak only as of the date hereof,
and Invitae Corporation disclaims any obligation to update these
forward-looking statements.
Invitae PR contact:
Amy
Hadsock
pr@invitae.com
(628) 213-3283
View original content to download
multimedia:https://www.prnewswire.com/news-releases/invitae-appoints-william-h-osborne-to-its-board-of-directors-301732813.html
SOURCE Invitae Corporation